In 2010, the Biologics Price Competition and Innovation Act was enacted in the United States to balance biologic innovation with fostering competition by establishing an abbreviated regulatory approval pathway for biosimilar drugs. Approved biosimilars are highly similar with no clinical difference to an already Food and Drug Administration (FDA)-approved biologic drug (i.e., "reference"). The complexity of manufacturing biologic products, coupled with lack of understanding about regulatory approval requirements for biosimilars, has led to lingering uncertainty among patients and healthcare providers regarding the comparative safety and effectiveness of these products. Real-world evidence can help alleviate stakeholder concerns by providing additional evidence beyond trials required for registration. To address the need for real-world evidence, the Academy of Managed Care Pharmacy convened the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) in 2015 as a nonprofit, multistakeholder, collaborative, and scientific initiative for conducting rigorous postmarketing observational research to monitor the effectiveness and safety of biosimilars and novel biologics. BBCIC leverages infrastructure from the FDA Sentinel Initiative, including a distributed research network (DRN) with access to curated data formatted in the Sentinel Common Data Model, and publicly available Sentinel analytic tools. BBCIC is governed as a collaboration between industry partners, health plans, patients, and the research community focusing on transparency and stakeholder engagement.